Abstract: Objective To investigate the clinical efficacy of combination of adefovir or entecavir and diammonium glycyrrhizinate in the treatment of patients with chronic hepatitis B （CHB）. Methods A total of 200 patients with CHB were recruited in our hospital between February 2013 and January 2016,and were randomly divided into control group （n=80） receiving diammonium glycyrrhizinate orally,or combination of adefovir （n=60） or entecavir and diammonium glycyrrhizinate（n=60） therapy for 12 months. The negative conversion rate of hepatitis B virus deoxyribonucleic acid （HBV DNA） and hepatitis B e antigen（HBeAg）,normalization rate of serum alanine aminotransferase（ALT）],and histological activity index（HAI） were compared among the three groups. Results There was no significant differences as respect to serum ALT,bilirubin and AST levels among the three groups before treatment（P>0.05）;At the end of 12 month treatment,the negative conversion rates of serum HBV DNA,negative conversion rates of serum HBeAg and normalization rates of ALT in the adefovir-treated group were 91.7%,18.3% and 86.7%,and were 88.3%,16.7%and 85.0% in entecavir-treated group,both significantly higher than 15.0%,6.3% and 51.3% in the diammonium glycyrrhizinate alone treated group （P<0.05 or P<0.01）;the HAI scores,ALT,TBIL and AST levels in the adefovir-treated group were（3.5±1.3）,（54.1±12.2） U/L,（16.4±4.1） μmol/L and （35.3±6.1） U/L,and were （3.2±1.5）,（53.4±13.0） U/L,（16.0±4.1）μmol/L and （34.1±6.3）U/L in the entecavir-treated group,significantly lower except TBIL and AST than （6.3±1.5）,（59.3±15.7） U/L,（18.0±4.5） μmol/L and（38.4±7.1） U/L in the diammonium glycyrrhizinate alone treated group（P<0.05）;there were no significant differences as respect to the above indexes between adefovir-treated and entecavir-treated groups （P>0.05）. Conclusion Combination of adefovir or entecavir and diammonium glycyrrhizinate in the treatment of patients with CHB is efficient,as the regimen might take an advantages in inhibiting replication of hepatitis B virus and alleviating the activity of inflammation in liver tissues.

Key words: Chronic hepatitis B, Adefovir, Entecavir, Diammonium glycyrrhizinate, Therapy